"In Indonesia, there has never been a vaccine that is totally Indonesia, 100 percent of the vaccine has never been made. The Red and White Vaccine will be the first."
Main Researcher of the Red and White Vaccine at Airlangga University (Unair), Dominic Husada, stated that the final phase of the Red and White Covid-19 Vaccine research started Indonesia's big step in starting the domestic pharmaceutical industry.
"In Indonesia there has never been a vaccine that is totally Indonesian, 100 percent of the vaccine has never been made. The Red and White vaccine will be the first, if it gives good results," said Dominic Husada, Wednesday (17/8/2022).
Husada said the attenuated virus platform vaccine was investigated by a team from Unair in collaboration with PT Biotis since May 12, 2020. Until now, the process has entered phase 3 clinical trials in the form of a second injection on 4,005 human subjects.
Husada added that the Red and White Vaccine virus was obtained from patients from hospitals (RS) in Surabaya, carried out at the Unair Laboratory by Prof. Fedik Abdul Rantam's team to become a vaccine candidate. After that, a series of additional tests were carried out in the Surabaya and Bogor laboratories and tested on animals in Surabaya and on humans.
"From the form of a virus to a vaccine, it is done in Indonesia, by Indonesians, for Indonesians," he said.
In the spirit of Indonesia's Independence today, the Red and White Vaccine is valuable for the research team to be presented to the nation.
"Although not as good as Pfizer's (imported) vaccine, the important thing is that we have made a big step forward," he said.
In phase 3 this time, research on vaccine subjects was carried out at Soetomo Hospital, Airlangga University Hospital Surabaya, Saiful Anwar Hospital Malang, Dr Soebandi Hospital Jember, and Pulmonary Hospital in Jember. The research requires the subject to go to the research laboratory. If they come from other cities around Surabaya, they get a substitute for transportation.
Phase 2 clinical trials also mark the final stage of the Red and White Vaccine research. If all reports are considered good by the Food and Drug Supervisory Agency (BPOM), the Red and White Vaccine Emergency Marketing Permit (EUA) will be issued in September or December 2022. (antara)
